Techniques to assess the proliferative potential of brain tumors

Alfredo Quinones-Hinojosa, Nader Sanai, Justin S. Smith, Michael W. McDermott

Research output: Contribution to journalReview article

55 Citations (Scopus)

Abstract

Assessment of brain tumor proliferative potential provides important prognostic information that supplements standard histopathologic grading. Many laboratories rely on mitotic figures to quantify the proliferative potential of brain tumors, but this conventional cellular proliferative index is subject to inter-observer variability and not consistently predictive for low-and high-grade tumors. Recent advancements in technology have made it possible to use proliferative indices as a standard supplement in pathology laboratories. Non-invasive tumor tissue measurements of cell proliferation can be performed using: bromodeoxyuridine labeling index (BrdU LI), flow cytometry (FCM), MIB-1 antibody to the Ki-67 antigen (MIB-1), proliferating cell nuclear antigen (PCNA), and argyrophilic nucleolar organizing regions (AgNOR). Each of these assays has been described in the literature with respect to its ability to predict tumor grade or outcome. At the present time MIB-1 and AgNOR are the simplest and most reliable of these techniques. In addition, advances in our understanding of the genetic alterations associated with proliferation promise to provide more specific markers of proliferative potential. Beyond the pathology laboratory, radiographic studies such as positron emission tomography (PET), single photon emission computed tomography (SPECT), and most recently magnetic resonance spectroscopy (MRS) have been used as follow-up measures, assessing response to treatment and tumor recurrence, rather than as predictors of response to treatment. These radiographic tools, however, have the potential to provide an assessment of tumor proliferation without the need for invasive measures. In this article, we present a review of the current techniques utilized to understand the proliferative potential of brain tumors.

Original languageEnglish (US)
Pages (from-to)19-30
Number of pages12
JournalJournal of Neuro-Oncology
Volume74
Issue number1
DOIs
StatePublished - Aug 2005
Externally publishedYes

Fingerprint

Brain Neoplasms
Neoplasms
Ki-67 Antigen
Pathology
Observer Variation
Proliferating Cell Nuclear Antigen
Bromodeoxyuridine
Single-Photon Emission-Computed Tomography
Positron-Emission Tomography
Flow Cytometry
Magnetic Resonance Spectroscopy
Cell Proliferation
Technology
Recurrence

Keywords

  • AgNOR
  • Brain tumor
  • BrdU
  • Flow cytometry
  • Ki-67
  • MIB-1
  • PCNA
  • PET
  • Proliferation index

ASJC Scopus subject areas

  • Clinical Neurology
  • Cancer Research
  • Oncology
  • Neuroscience(all)

Cite this

Techniques to assess the proliferative potential of brain tumors. / Quinones-Hinojosa, Alfredo; Sanai, Nader; Smith, Justin S.; McDermott, Michael W.

In: Journal of Neuro-Oncology, Vol. 74, No. 1, 08.2005, p. 19-30.

Research output: Contribution to journalReview article

Quinones-Hinojosa, Alfredo ; Sanai, Nader ; Smith, Justin S. ; McDermott, Michael W. / Techniques to assess the proliferative potential of brain tumors. In: Journal of Neuro-Oncology. 2005 ; Vol. 74, No. 1. pp. 19-30.
@article{c0d24880c86846ed84278134406cb126,
title = "Techniques to assess the proliferative potential of brain tumors",
abstract = "Assessment of brain tumor proliferative potential provides important prognostic information that supplements standard histopathologic grading. Many laboratories rely on mitotic figures to quantify the proliferative potential of brain tumors, but this conventional cellular proliferative index is subject to inter-observer variability and not consistently predictive for low-and high-grade tumors. Recent advancements in technology have made it possible to use proliferative indices as a standard supplement in pathology laboratories. Non-invasive tumor tissue measurements of cell proliferation can be performed using: bromodeoxyuridine labeling index (BrdU LI), flow cytometry (FCM), MIB-1 antibody to the Ki-67 antigen (MIB-1), proliferating cell nuclear antigen (PCNA), and argyrophilic nucleolar organizing regions (AgNOR). Each of these assays has been described in the literature with respect to its ability to predict tumor grade or outcome. At the present time MIB-1 and AgNOR are the simplest and most reliable of these techniques. In addition, advances in our understanding of the genetic alterations associated with proliferation promise to provide more specific markers of proliferative potential. Beyond the pathology laboratory, radiographic studies such as positron emission tomography (PET), single photon emission computed tomography (SPECT), and most recently magnetic resonance spectroscopy (MRS) have been used as follow-up measures, assessing response to treatment and tumor recurrence, rather than as predictors of response to treatment. These radiographic tools, however, have the potential to provide an assessment of tumor proliferation without the need for invasive measures. In this article, we present a review of the current techniques utilized to understand the proliferative potential of brain tumors.",
keywords = "AgNOR, Brain tumor, BrdU, Flow cytometry, Ki-67, MIB-1, PCNA, PET, Proliferation index",
author = "Alfredo Quinones-Hinojosa and Nader Sanai and Smith, {Justin S.} and McDermott, {Michael W.}",
year = "2005",
month = "8",
doi = "10.1007/s11060-004-5758-0",
language = "English (US)",
volume = "74",
pages = "19--30",
journal = "Journal of Neuro-Oncology",
issn = "0167-594X",
publisher = "Kluwer Academic Publishers",
number = "1",

}

TY - JOUR

T1 - Techniques to assess the proliferative potential of brain tumors

AU - Quinones-Hinojosa, Alfredo

AU - Sanai, Nader

AU - Smith, Justin S.

AU - McDermott, Michael W.

PY - 2005/8

Y1 - 2005/8

N2 - Assessment of brain tumor proliferative potential provides important prognostic information that supplements standard histopathologic grading. Many laboratories rely on mitotic figures to quantify the proliferative potential of brain tumors, but this conventional cellular proliferative index is subject to inter-observer variability and not consistently predictive for low-and high-grade tumors. Recent advancements in technology have made it possible to use proliferative indices as a standard supplement in pathology laboratories. Non-invasive tumor tissue measurements of cell proliferation can be performed using: bromodeoxyuridine labeling index (BrdU LI), flow cytometry (FCM), MIB-1 antibody to the Ki-67 antigen (MIB-1), proliferating cell nuclear antigen (PCNA), and argyrophilic nucleolar organizing regions (AgNOR). Each of these assays has been described in the literature with respect to its ability to predict tumor grade or outcome. At the present time MIB-1 and AgNOR are the simplest and most reliable of these techniques. In addition, advances in our understanding of the genetic alterations associated with proliferation promise to provide more specific markers of proliferative potential. Beyond the pathology laboratory, radiographic studies such as positron emission tomography (PET), single photon emission computed tomography (SPECT), and most recently magnetic resonance spectroscopy (MRS) have been used as follow-up measures, assessing response to treatment and tumor recurrence, rather than as predictors of response to treatment. These radiographic tools, however, have the potential to provide an assessment of tumor proliferation without the need for invasive measures. In this article, we present a review of the current techniques utilized to understand the proliferative potential of brain tumors.

AB - Assessment of brain tumor proliferative potential provides important prognostic information that supplements standard histopathologic grading. Many laboratories rely on mitotic figures to quantify the proliferative potential of brain tumors, but this conventional cellular proliferative index is subject to inter-observer variability and not consistently predictive for low-and high-grade tumors. Recent advancements in technology have made it possible to use proliferative indices as a standard supplement in pathology laboratories. Non-invasive tumor tissue measurements of cell proliferation can be performed using: bromodeoxyuridine labeling index (BrdU LI), flow cytometry (FCM), MIB-1 antibody to the Ki-67 antigen (MIB-1), proliferating cell nuclear antigen (PCNA), and argyrophilic nucleolar organizing regions (AgNOR). Each of these assays has been described in the literature with respect to its ability to predict tumor grade or outcome. At the present time MIB-1 and AgNOR are the simplest and most reliable of these techniques. In addition, advances in our understanding of the genetic alterations associated with proliferation promise to provide more specific markers of proliferative potential. Beyond the pathology laboratory, radiographic studies such as positron emission tomography (PET), single photon emission computed tomography (SPECT), and most recently magnetic resonance spectroscopy (MRS) have been used as follow-up measures, assessing response to treatment and tumor recurrence, rather than as predictors of response to treatment. These radiographic tools, however, have the potential to provide an assessment of tumor proliferation without the need for invasive measures. In this article, we present a review of the current techniques utilized to understand the proliferative potential of brain tumors.

KW - AgNOR

KW - Brain tumor

KW - BrdU

KW - Flow cytometry

KW - Ki-67

KW - MIB-1

KW - PCNA

KW - PET

KW - Proliferation index

UR - http://www.scopus.com/inward/record.url?scp=23944503109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=23944503109&partnerID=8YFLogxK

U2 - 10.1007/s11060-004-5758-0

DO - 10.1007/s11060-004-5758-0

M3 - Review article

C2 - 16078103

AN - SCOPUS:23944503109

VL - 74

SP - 19

EP - 30

JO - Journal of Neuro-Oncology

JF - Journal of Neuro-Oncology

SN - 0167-594X

IS - 1

ER -